Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP grew its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 76.5% during the fourth quarter, HoldingsChannel reports. The firm owned 33,104 shares of the company’s stock after purchasing an additional 14,343 shares during the quarter. GSA Capital Partners LLP’s holdings in Centessa Pharmaceuticals were worth $828,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. TD Waterhouse Canada Inc. acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $25,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after purchasing an additional 979 shares during the period. DNB Asset Management AS acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $218,000. Sigma Planning Corp acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $225,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Centessa Pharmaceuticals by 3,028.1% in the second quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock valued at $460,000 after purchasing an additional 33,854 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $39.75 on Friday. The business’s 50 day simple moving average is $36.56 and its 200-day simple moving average is $29.36. The firm has a market capitalization of $5.93 billion, a price-to-earnings ratio of -22.21 and a beta of 1.13. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $10.95 and a 12 month high of $40.26. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Gregory M. Weinhoff sold 73,196 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the sale, the insider owned 65,925 shares of the company’s stock, valued at $1,735,805.25. This trade represents a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the transaction, the insider owned 62,085 shares in the company, valued at $1,870,000.20. This trade represents a 39.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 309,112 shares of company stock worth $8,424,535. Corporate insiders own 4.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CNTA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. B. Riley Financial lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, Leerink Partners lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their price objective for the stock from $36.00 to $40.00 in a report on Wednesday, April 1st. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $40.70.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.